Cargando…

Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—A Post Hoc Analysis

Our study aims to develop an effective integrated machine learning (ML) scheme to predict vascular events and bleeding in patients with nonvalvular atrial fibrillation taking dabigatran and identify important risk factors. This study is a post-hoc analysis from the Randomized Evaluation of Long-Term...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yung-Chuan, Cheng, Yu-Chen, Jhou, Mao-Jhen, Chen, Mingchih, Lu, Chi-Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146635/ https://www.ncbi.nlm.nih.gov/pubmed/35629177 http://dx.doi.org/10.3390/jpm12050756

Ejemplares similares

Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran
por: Huang, Yung-Chuan, et al.
Publicado: (2023)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation
por: Bachvarova, Velislava, et al.
Publicado: (2017)

Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran
por: Xiong, Yurong, et al.
Publicado: (2020)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions
por: Ferreira, Jorge, et al.
Publicado: (2012)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin
por: Watanabe, Tetsuya, et al.
Publicado: (2016)

Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
por: Silva, Vanessa M., et al.
Publicado: (2019)

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review
por: Milling, Truman J., et al.
Publicado: (2017)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
por: Li, Xiaoye, et al.
Publicado: (2021)

Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011)

Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
por: Kinjo, Norito, et al.
Publicado: (2023)

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
por: Koretsune, Yukihiro, et al.
Publicado: (2019)

Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study
por: Yamamoto, Tomohiko, et al.
Publicado: (2020)

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study
por: Xiang, Qian, et al.
Publicado: (2022)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States
por: Jain, Rahul, et al.
Publicado: (2018)

Right atrium thrombosis in nonvalvular permanent atrial fibrillation
por: Bălăceanu, A.
Publicado: (2011)

Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation
por: Sen, Souvik, et al.
Publicado: (2014)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Altered profile of circulating microparticles in nonvalvular atrial fibrillation
por: Siwaponanan, Panjaree, et al.
Publicado: (2019)

Left Atrial Appendage Depth and Tachycardia Bradycardia Syndrome as Important Predictors of Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation
por: He, Yinge, et al.
Publicado: (2022)

Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Collado, Fareed Moses S., et al.
Publicado: (2021)

Left atrial appendage closure in nonvalvular atrial fibrillation patients with percutaneous coronary intervention
por: Yu, Yunan, et al.
Publicado: (2022)

Effects of Left Atrial Appendage Closure on Neuroendocrine Function in Patients with Nonvalvular Atrial Fibrillation
por: Wang, Fei, et al.
Publicado: (2022)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012)

Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)

Nonvalvular atrial fibrillation in India—time to pause, think, and change!
por: Singh, Balbir
Publicado: (2018)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021)

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
por: Tamayo, Sally, et al.
Publicado: (2015)

Characteristics, Thrombus Resolution, and Long-Term Outcomes in Patients with Nonvalvular Atrial Fibrillation and Atrial Thrombus
por: Yang, Shu, et al.
Publicado: (2023)

Appropriateness of dabigatran dosing in patients with nonvalvular atrial fibrillation (NVAF): A retrospective study conducted in a tertiary care university hospital in the eastern province of Saudi Arabia
por: Alali, Nasser, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b21r46g5mtiot9to0vr4rqjmo1